NuvaRing Lawsuit Over Serious Side Effects. Have you suffered a serious injury from NuvaRing, a birth control device marketed by Organon Pharmaceuticals? Since being approved by the U.S. Food & Drug Administration (FDA) in 2001, NuvaRing has been associated with a number of serious and potentially fatal side effects, including:
- Blood clot
- Deep vein thrombosis (DVT)
- Pulmonary embolism (PE)
- Heart Attack
Lawyers at Parker Waichman LLP are currently investigating potential legal claims on behalf of women who suffered any of the above NuvaRing side effects. If you were injured by NuvaRing, you may be entitled to compensation for your medical bills, lost wages, and pain and suffering. Our NuvaRing lawyers are offering free lawsuit consultations to anyone who suffered blood clots, DVT, PE, stroke or heart attack while using this device. If you were the victim of a NuvaRing injury, please contact Parker Waichman LLP today to protect your legal rights.
NuvaRing is a once-a-month contraceptive that consists of a small plastic ring that is inserted into the vagina and remains there for a three week period. NuvaRing releases a combination of ethinyl estradiol, a form of the hormone estrogen, and etonogestral. Etonogestral is an active metabolite of desogestrel, a form of the hormone progestin.
All hormonal contraceptives carry some risk of cardiac side effects, including blood clots, DVT, PE, heart attacks and strokes. But plaintiffs in NuvaRing lawsuits claim such side effects occur more frequently among women who use NuvaRing, compared to those on other types of hormonal birth control. Hundreds of lawsuits alleging NuvaRing caused users to suffer these serious side effects are currently pending in a multidistrict litigation in U.S. District Court, Eastern District of Missouri.
NuvaRing releases a combination of ethinyl estradiol, a form of the hormone estrogen, and etonogestral. Etonogestral is an active metabolite of desogestrel, a form of the hormone progestin. In 2003, the New England Journal of Medicine published two studies that concluded that the use of low-estrogen oral contraceptives containing desogestrel significantly increases the risk of venous thromboembolism, a potentially fatal type of blood clot, more than low-estrogen birth control pills containing levonorgestrel. In 2007, the consumer advocacy group Public Citizen asked the FDA to ban oral contraceptives that contained forms of desogestral because this dangerous progestin has been implicated in a higher risk of strokes, blood clots and other cardiovascular problems.